TNGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Tango Therapeutics's 3-Year RORE % for the quarter that ended in Jun. 2024 was 0.58%.
The industry rank for Tango Therapeutics's 3-Year RORE % or its related term are showing as below:
The historical data trend for Tango Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
3-Year RORE % | - | - | - | 11.92 |
Tango Therapeutics Quarterly Data | ||||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
3-Year RORE % | Get a 7-Day Free Trial | 21.13 | 19.08 | 11.92 | 7.37 | 0.58 |
For the Biotechnology subindustry, Tango Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tango Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Tango Therapeutics's 3-Year RORE % falls into.
Tango Therapeutics's 3-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:
3-Year RORE % | = | ( Most Recent EPS (Diluted) | - | First Period EPS (Diluted) ) | / | ( Cumulative EPS (Diluted) for 3-year | - | Cumulative Dividends per Share for 3-year ) |
= | ( -1.12 | - | -1.1 ) | / | ( -3.43 | - | 0 ) | |
= | -0.02 | / | -3.43 | |||||
= | 0.58 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 3-year before.
Tango Therapeutics (NAS:TNGX) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Thank you for viewing the detailed overview of Tango Therapeutics's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Third Rock Ventures Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Mva Investors, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Lesley Ann Calhoun | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Douglas Barry | officer: See Remarks | TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142 |
Adam Crystal | officer: See Remarks | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Barbara Weber | director, officer: Chief Executive Officer | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Daniella Beckman | officer: Chief Financial Officer | C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139 |
Boxer Capital, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
John B Ketchum | director | TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215 |
Joseph Lewis | other: See remarks | PO BOX N7776, LYFORD BAHAMAS |
Trv Gp Vi, Llc | director | 201 BROOKLINE AVE., BOSTON MA 02215 |
Third Rock Ventures Gp Vi, L.p. | director | 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215 |
Third Rock Ventures Vi, L.p. | director | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Boxer Asset Management Inc. | other: See remarks | CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 10-12-2023
By GuruFocus Research • 08-07-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 11-07-2023
By Business Wire • 04-01-2024
By Marketwired • 09-05-2023
By Marketwired • 09-06-2023
By GuruFocus Research • 10-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.